Do bisphosphonates and RANKL inhibitors alter the progression of coronary artery calcification? A systematic review.

ABSTRACT:

Objectives

To determine whether bisphosphonates and NF-κB ligand (RANKL) inhibitors delay coronary artery calcification (CAC).

Design

A systematic review was conducted.

Data sources

MEDLINE, EMBASE and CENTRAL.

Eligibility criteria

Longitudinal studies investigating CAC progression in adults (>18 years) taking either a bisphosphonate or denosumab compared with those who did not.

Data extraction and synthesis

Study and participant characteristics, and primary outcome ( ∆ CAC from baseline to follow-up) were extracted. The Risk Of Bias In Non-Randomised Studies-of Interventions (ROBINS-I) and Risk-of-Bias Tool for Randomised Trials (RoB2) tools were used to assess the risk of bias for observational and randomised controlled trials (RCTs), respectively. Out

SUBMITTER: Saunders SL 

PROVIDER: S-EPMC11429268 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature